Clinical Translational Research Award – HT9425-23-MBRP-CTRA
- up to USD42M over 4 years
- Preproposals due 31 May 2023
- supports human research projects that are likely to have a major impact on patient care by applying promising and well-founded research findings to the care of the burn-injured patient, particularly at the point of injury, or during the acute phase of injury.
- must include clinical research, and may include initial proof-of-concept trials, studies involving use of human anatomical substances, observational studies, and/or involve some retrospective data analysis
- large randomized clinical trials are discouraged
- preliminary data required
- animal research not supported
Technology/Therapeutic Development Award – HT9425-23-MBRP-TTDA
- up to USD$2M over 4 years
- Preproposals due 31 May 2023
- supports the translation of promising preclinical findings into products for clinical applications.
- Product-oriented (eg device, drug, clinical guidelines). The product(s) to be developed may be a tangible item such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product.
- Proof of concept demonstrating the potential utility of the proposed product, or a prototype/preliminary version of the proposed product, should already be established.
- Preliminary data required.
- Clinical trials not allowed
Supporting documents
- Reference table of award mechanisms – 23mbrpreftable
- Clinical Translation Research Award – HT9425-23-MBRP-CTRA
- Technology/Therapeutic Development Award – HT9425-23-MBRP-TTDA